GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IO Biotech Inc (NAS:IOBT) » Definitions » 1-Year ROIIC %

IOBT (IO Biotech) 1-Year ROIIC % : -1,302.42% (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is IO Biotech 1-Year ROIIC %?

1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year. IO Biotech's 1-Year ROIIC % for the quarter that ended in Sep. 2024 was -1,302.42%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for IO Biotech's 1-Year ROIIC % or its related term are showing as below:

IOBT's 1-Year ROIIC % is ranked worse than
93.39% of 1422 companies
in the Biotechnology industry
Industry Median: -11.235 vs IOBT: -1302.42

IO Biotech 1-Year ROIIC % Historical Data

The historical data trend for IO Biotech's 1-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IO Biotech 1-Year ROIIC % Chart

IO Biotech Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
1-Year ROIIC %
- 2.86 -1,760.41 -598.65 -2,369.88

IO Biotech Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
1-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3,879.31 -2,369.88 1,065.72 3,203.21 -1,302.42

Competitive Comparison of IO Biotech's 1-Year ROIIC %

For the Biotechnology subindustry, IO Biotech's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IO Biotech's 1-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IO Biotech's 1-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where IO Biotech's 1-Year ROIIC % falls into.



IO Biotech 1-Year ROIIC % Calculation

IO Biotech's 1-Year ROIIC % for the quarter that ended in Sep. 2024 is calculated as:

1-Year ROIIC %=1-Year Incremental Net Operating Profit After Taxes (NOPAT)**/1-Year Incremental Invested Capital
=( -97.8728 (Sep. 2024) - -85.2393 (Sep. 2023) )/( 9.322 (Sep. 2024) - 8.352 (Sep. 2023) )
=-12.6335/0.97
=-1,302.42%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


IO Biotech  (NAS:IOBT) 1-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


IO Biotech 1-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of IO Biotech's 1-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


IO Biotech Business Description

Traded in Other Exchanges
N/A
Address
Ole Maaloes Vej 3, Copenhagen N, DNK, DK-2200
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
Executives
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Brian Burkavage officer: Chief Accounting Officer C/O PASSAGE BIO, INC., ONE COMMERCE SQUARE, 39TH FLOOR, PHILADELPHIA PA 19103
Heidi Hunter director C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080
Partners Kurma 10 percent owner 24 RUE ROYALE, PARIS I0 75008
Vivo Opportunity Fund Holdings, L.p. 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Devin Whittemore Smith officer: General Counsel C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Vivo Capital Fund Ix, L.p. 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Vivo Opportunity, Llc 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Qasim Iftikhar Ahmad officer: Chief Medical Officer 1209 ORANGE STREET, WILMINGTON DE 19801
Amy Sullivan officer: Chief Financial Officer 38 OUTLOOK ROAD, SWAMPSCOTT MA 01907
David V Smith director 6035 STONERIDGE DRIVE, PLEASANTON CA 94588
Lundbeckfond Invest A/s 10 percent owner SCHERFIGSVEJ 7, COPENHAGEN G7 DK-2100
Jack Nielsen director C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Vanessa Malier director 1209 ORANGE STREET, WILLMINGTON DE 19801
Claus A. Andersson director 1209 ORANGE STREET, WILMINGTON DE 19801

IO Biotech Headlines

From GuruFocus

IO Biotech Announces 2023 Second Quarter Results

By Marketwired 08-11-2023

IO Biotech Announces Appointment of Devin Smith as General Counsel

By Stock market mentor Stock market mentor 01-23-2023

IO Biotech to Present at the Jefferies Healthcare Conference

By sperokesalga sperokesalga 05-30-2023